D1 dopamine receptor agonist compounds, pharmaceutical composition and their use

摘要

Invention Patent: "DOPAMINE D1 RECEPTOR AGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND ITS USE". The invention provides 2,3,4,5-tetrahydro-1H-3-benzazepines of general formula (I) in which: R ^ 1 ^ is hydrogen, halogen, C ~ 1 ~ -C ~ 4 ~ alkyl, or CF ~ 3 ~; R ^ 2 ^ is hydrogen, methyl, or lower alkenyl of 3 to 5 carbon atoms; R ^ 3 ^ and R ^ 4 ^ together form a furan, dihydrofuran, thiophene, dihydrothiophene, cyclopentane or cyclohexane ring and R ^ 5 ~ is hydrogen or R ^ 4 ^ and R ^ 5 ~ together form a furan, dihydrofuran ring , thiophene, dihydrothiophene, cyclopentane or cyclohexane and R ^ 3 ^ is hydrogen; R ^ 6 ^ is hydrogen, halogen, CF ~ 3 ~, CN, N0 ~ 2 ~ or NH ~ 2 ~; R ^ 7 ^ is hydrogen, halogen, CF ~ 3 ~, CN, NO ~ 2 ~ or NH ~ 2 ~. The specific combination of substituents: R ~ 1 ~ = H, R ~ 2 ~ = H and R ~ 4 ~ and R ~ 5 ~ together forming a cyclohexane ring is excluded, namely 1- (5,6,7,8 -tetrahydronaphthalen-2-yl) - 2,3,4,5-tetrahydro-1 H -benzo [d] azepine-7,8-diol. The compounds of the invention provide therapeutic agents that selectively interact positively with postsynaptic dopamine D1 receptors in the striatum, directly or indirectly (called dopamine D1 agonists) and are particularly valuable as anti-Parkinsonian agents.